Dermatologicals Market by Dermatological Disease (Acne, Dermatitis, Psoriasis, Skin Cancer, Rosacea, and Alopecia), Drug Type (Prescription-Based Drugs and Over-the-Counter Drugs), and Route of Administration (Topical, Oral, and Parenteral Administration), Global Opportunity Analysis and Industry Forecast, 2018–2026
- ALL3848240
- 245 Pages
- March 2020
- Healthcare
Dermatologicals are medicinal preparations used to treat patients suffering from skin disorders. These preparations are used to treat conditions such as psoriasis, acne, and rosacea. Moreover, there are different types of dermatological formulations available in the market such as topical, and oral. Furthermore, skin disorders are different from each other and therefore, require different treatment options. For instance, disorders such as psoriasis require the use of parenteral dermatological preparations for treatment. In addition, these preparations are mostly available over-the-counter. However, some of the preparations are also prescribed by physicians.
The major factor that contributes to the growth of dermatologicals market include rise in demand for topical dermatological drugs such as anti-inflammatory agents, anti-infective, local anesthetics, cleansers, and emollients to treat acne. Furthermore, the rise in awareness about skin diseases, high demand for rapid diagnosis, and surge in incidence of skin cancer & other skin disorders are the factors that boost the growth of the market. However, lack of awareness about these drugs and stringent government regulations restrain the market growth. The development of innovative products and rise in number of mergers & acquisitions by key vendors are expected to provide numerous opportunities for the market growth during the forecast period.
The dermatologicals market size is studied on the basis of dermatological disease, drug type, route of administration, and region to provide a detailed assessment of the market. On the basis of dermatological disease, it is segmented into acne, dermatitis, psoriasis, skin cancer, rosacea, alopecia, and others. By drug type, it is bifurcated into prescription-based drugs and over-the-counter drugs. On the basis of route of administration, it is segmented into topical, oral, and parenteral administration. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
• This report entails a detailed quantitative analysis along with the current global dermatologicals market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessments.
• The market size and estimations are based on a comprehensive analysis of key developments in the industry.
• A qualitative analysis based on innovative products facilitates strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Key Market Segments
• By Dermatological Disease
o Acne
o Dermatitis
o Psoriasis
o Skin Cancer
o Rosacea
o Alopecia
o Others
• By Drug Type
o Prescription-Based Drugs
o Over-the-Counter Drugs
• By Route of Administration
o Topical
o Oral
o Parenteral Administration
• By Region
o North America
U.S.
Canada
Mexico
o Europe
Germany
France
UK
Italy
Spain
Rest of Europe
o Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
o LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
• List of key players profiled in the report:
• Bayer AG
• Johnson & Johnson
• Pfizer Inc.
• Novartis AG
• GlaxoSmithKline plc
• AstraZeneca
• Galderma S.A.
• Amgen Inc.
• AbbVie Inc.,
• Merck KGaA
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
• Bausch Health Companies Inc.
• Sienna Biopharmaceuticals
1.1. Report description
1.2. Key market segments
1.2.1. List of key players profiled in the report
1.3. Research methodology
1.3.1. Primary research
1.3.2. Secondary research
1.3.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Top player positioning
3.2.1. Top investment pockets
3.3. Key forces shaping dermatologicals industry/market
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in prevalence of skin disorders
3.4.1.2. Surge in healthcare expenditure worldwide
3.4.1.3. Rise in focus on skin care products
3.4.2. Restraint
3.4.2.1. Presence of alternatives for acne treatment
3.4.3. Opportunity
3.4.3.1. High growth potential in developing economies
3.4.4. Impact Analyses
CHAPTER 4: DERMATOLOGICALS MARKET, BY DISEASE
4.1. Overview
4.1.1. Market size and forecast
4.2. Acne
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Dermatitis
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Psoriasis
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Skin Cancer
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
4.6. Rosacea
4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country
4.7. Alopecia
4.7.1. Key market trends, growth factors, and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market analysis, by country
4.8. Others
4.8.1. Key market trends, growth factors, and opportunities
4.8.2. Market size and forecast, by region
4.8.3. Market analysis, by country
CHAPTER 5: DERMATOLOGICALS MARKET, BY TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Prescription-Based Drugs
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Over-the-Counter Drugs
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
CHAPTER 6: DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Topical Administration
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Oral Administration
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
6.4. Parenteral Administration
6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country
CHAPTER 7: DERMATOLOGICALS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends and opportunities
7.2.2. Market analysis, by country
7.2.2.1. U.S.
7.2.2.1.1. U.S. market size and forecast, by disease
7.2.2.1.2. U.S. market size and forecast, by type
7.2.2.1.3. U.S. market size and forecast, by route of administration
7.2.2.2. Canada
7.2.2.2.1. Canada market size and forecast, by disease
7.2.2.2.2. Canada market size and forecast, by type
7.2.2.2.3. Canada market size and forecast, by route of administration
7.2.2.3. Mexico
7.2.2.3.1. Mexico market size and forecast, by disease
7.2.2.3.2. Mexico market size and forecast, by type
7.2.2.3.3. Mexico market size and forecast, by route of administration
7.2.3. North America market size and forecast, by disease
7.2.4. North America market size and forecast, by type
7.2.5. North America market size and forecast, by route of administration
7.3. Europe
7.3.1. Key market trends and opportunities
7.3.2. Market analysis, by country
7.3.2.1. Germany
7.3.2.1.1. Germany market size and forecast, by disease
7.3.2.1.2. Germany market size and forecast, by type
7.3.2.1.3. Germany market size and forecast, by route of administration
7.3.2.2. France
7.3.2.2.1. France market size and forecast, by disease
7.3.2.2.2. France market size and forecast, by type
7.3.2.2.3. France market size and forecast, by route of administration
7.3.2.3. UK
7.3.2.3.1. UK market size and forecast, by dermatological disease
7.3.2.3.2. UK market size and forecast, by type
7.3.2.3.3. UK market size and forecast, by route of administration
7.3.2.4. Italy
7.3.2.4.1. Italy market size and forecast, by dermatological disease
7.3.2.4.2. Italy market size and forecast, by type
7.3.2.4.3. Italy market size and forecast, by route of administration
7.3.2.5. Rest of Europe
7.3.2.5.1. Rest of Europe market size and forecast, by dermatological disease
7.3.2.5.2. Rest of Europe market size and forecast, by type
7.3.2.5.3. Rest of Europe market size and forecast, by route of administration
7.3.3. Europe market size and forecast, by dermatological disease
7.3.4. Europe market size and forecast, by type
7.3.5. Europe market size and forecast, by route of administration
7.4. Asia-Pacific
7.4.1. Key market trends and opportunities
7.4.2. Market analysis, by country
7.4.2.1. Japan
7.4.2.1.1. Japan market size and forecast, by dermatological disease
7.4.2.1.2. Japan market size and forecast, by type
7.4.2.1.3. Japan market size and forecast, by route of administration
7.4.2.2. China
7.4.2.2.1. China market size and forecast, by dermatological disease
7.4.2.2.2. China market size and forecast, by type
7.4.2.2.3. China market size and forecast, by route of administration
7.4.2.3. India
7.4.2.3.1. India market size and forecast, by dermatological disease
7.4.2.3.2. India market size and forecast, by type
7.4.2.3.3. India market size and forecast, by route of administration
7.4.2.4. Rest of Asia-Pacific
7.4.2.4.1. Rest of Asia-Pacific market size and forecast, by dermatological disease
7.4.2.4.2. Rest of Asia-Pacific market size and forecast, by type
7.4.2.4.3. Rest of Asia-Pacific market size and forecast, by route of administration
7.4.3. Asia-Pacific market size and forecast, by dermatological disease
7.4.4. Asia-Pacific market size and forecast, by type
7.4.5. Asia-Pacific market size and forecast, by route of administration
7.5. LAMEA
7.5.1. Key market trends and opportunities
7.5.2. Market analysis, by country
7.5.2.1. Brazil
7.5.2.1.1. Brazil market size and forecast, by dermatological disease
7.5.2.1.2. Brazil market size and forecast, by type
7.5.2.1.3. Brazil market size and forecast, by route of administration
7.5.2.2. South Africa
7.5.2.2.1. South Africa market size and forecast, by dermatological disease
7.5.2.2.2. South Africa market size and forecast, by type
7.5.2.2.3. South Africa market size and forecast, by route of administration
7.5.2.3. Saudi Arabia
7.5.2.3.1. Saudi Arabia market size and forecast, by dermatological disease
7.5.2.3.2. Saudi Arabia market size and forecast, by type
7.5.2.3.3. Saudi Arabia market size and forecast, by route of administration
7.5.2.4. Rest of LAMEA
7.5.2.4.1. Rest of LAMEA market size and forecast, by dermatological disease
7.5.2.4.2. Rest of LAMEA market size and forecast, by type
7.5.2.4.3. Rest of LAMEA market size and forecast, by route of administration
7.5.3. LAMEA market size and forecast, by dermatological disease
7.5.4. LAMEA market size and forecast, by type
7.5.5. LAMEA market size and forecast, by route of administration
CHAPTER 8: COMPANY PROFILES
8.1. AbbVie Inc.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.2. AstraZeneca plc
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. Amgen Inc.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.4. GlaxoSmithKline Plc.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.5. Johnson & Johnson
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.6. Leo Pharma A/S
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments
8.7. Merck KGaA
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.8. Nestlé S.A
8.8.1. Company overview
8.8.2. Operating business segments
8.8.3. Business performance
8.9. Novartis AG
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.10. Pfizer Inc.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
TABLE 01. GLOBAL DERMATOLOGICALS MARKET, BY DISEASE, 2018–2026 ($MILLION)
TABLE 02. ACNE DERMATOLOGICALS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 03. DERMATITIS DERMATOLOGICALS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 04. PSORIASIS DERMATOLOGICALS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 05. SKIN CANCER DERMATOLOGICALS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 06. ROSACEA DERMATOLOGICALS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 07. ALOPECIA DERMATOLOGICALS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 08. OTHERS DERMATOLOGICALS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 09. GLOBAL DERMATOLOGICALS MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 10. PRESCRIPTION-BASED DERMATOLOGICALS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 11. OVER-THE-COUNTER DERMATOLOGICALS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 12. GLOBAL DERMATOLOGICALS MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 13. TOPICAL ADMINISTRATION MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 14. ORAL ADMINISTRATION DERMATOLOGICALS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 15. PARENTERAL ADMINISTRATION DERMATOLOGICALS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 16. DERMATOLOGICALS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 17. NORTH AMERICA DERMATOLOGICALS MARKET REVENUE, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 18. U.S. DERMATOLOGICALS MARKET REVENUE, BY DISEASE, 2018–2026 ($MILLION)
TABLE 19. U.S. DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026 ($MILLION)
TABLE 20. U.S. DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 21. CANADA DERMATOLOGICALS MARKET REVENUE, BY DISEASE, 2018–2026 ($MILLION)
TABLE 22. CANADA DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026 ($MILLION)
TABLE 23. CANADA DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 24. MEXICO DERMATOLOGICALS MARKET REVENUE, BY DISEASE, 2018–2026 ($MILLION)
TABLE 25. MEXICO DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026 ($MILLION)
TABLE 26. MEXICO DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 27. NORTH AMERICA DERMATOLOGICALS MARKET REVENUE, BY DISEASE, 2018–2026($MILLION)
TABLE 28. NORTH AMERICA DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026($MILLION)
TABLE 29. NORTH AMERICA DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINSTRATION, 2018–2026($MILLION)
TABLE 30. EUROPE DERMATOLOGICALS MARKET REVENUE, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 31. GERMANY DERMATOLOGICALS MARKET REVENUE, BY DISEASE, 2018–2026 ($MILLION)
TABLE 32. GERMANY DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026 ($MILLION)
TABLE 33. GERMANY DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 34. FRANCE DERMATOLOGICALS MARKET REVENUE, BY DISEASE, 2018–2026 ($MILLION)
TABLE 35. FRANCE DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026 ($MILLION)
TABLE 36. FRANCE DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 37. UK DERMATOLOGICALS MARKET REVENUE, BY DERMATOLOGICAL DISEASE, 2018–2026 ($MILLION)
TABLE 38. UK DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026 ($MILLION)
TABLE 39. UK DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 40. ITALY DERMATOLOGICALS MARKET REVENUE, BY DERMATOLOGICAL DISEASE, 2018–2026 ($MILLION)
TABLE 41. ITALY DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026 ($MILLION)
TABLE 42. ITALY DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 43. REST OF EUROPE DERMATOLOGICALS MARKET REVENUE, BY DERMATOLOGICAL DISEASE, 2018–2026 ($MILLION)
TABLE 44. REST OF EUROPE DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026 ($MILLION)
TABLE 45. REST OF EUROPE DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 46. EUROPE DERMATOLOGICALS MARKET REVENUE, BY DERMATOLOGICAL DISEASE, 2018–2026($MILLION)
TABLE 47. EUROPE DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026($MILLION)
TABLE 48. EUROPE DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINSITRATION, 2018–2026($MILLION)
TABLE 49. ASIA-PACIFIC DERMATOLOGICALS MARKET REVENUE, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 50. JAPAN DERMATOLOGICALS MARKET REVENUE, BY DERMATOLOGICAL DISEASE, 2018–2026 ($MILLION)
TABLE 51. JAPAN DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026 ($MILLION)
TABLE 52. JAPAN DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 53. CHINA DERMATOLOGICALS MARKET REVENUE, BY DERMATOLOGICAL DISEASE, 2018–2026 ($MILLION)
TABLE 54. CHINA DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026 ($MILLION)
TABLE 55. CHINA DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 56. INDIA DERMATOLOGICALS MARKET REVENUE, BY DERMATOLOGICAL DISEASE, 2018–2026 ($MILLION)
TABLE 57. INDIA DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026 ($MILLION)
TABLE 58. INDIA DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 59. REST OF ASIA-PACIFIC DERMATOLOGICALS MARKET REVENUE, BY DERMATOLOGICAL DISEASE, 2018–2026 ($MILLION)
TABLE 60. REST OF ASIA-PACIFIC DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026 ($MILLION)
TABLE 61. REST OF ASIA-PACIFIC DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 62. ASIA-PACIFIC DERMATOLOGICALS MARKET REVENUE, BY DERMATOLOGICAL DISEASE, 2018–2026($MILLION)
TABLE 63. ASIA-PACIFIC DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026($MILLION)
TABLE 64. ASIA-PACIFIC DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINSTRATION, 2018–2026($MILLION)
TABLE 65. LAMEA DERMATOLOGICALS MARKET REVENUE, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 66. BRAZIL DERMATOLOGICALS MARKET REVENUE, BY DERMATOLOGICAL DISEASE, 2018–2026 ($MILLION)
TABLE 67. BRAZIL DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026 ($MILLION)
TABLE 68. BRAZIL DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 69. SOUTH AFRICA DERMATOLOGICALS MARKET REVENUE, BY DERMATOLOGICAL DISEASE, 2018–2026 ($MILLION)
TABLE 70. SOUTH AFRICA DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026 ($MILLION)
TABLE 71. SOUTH AFRICA DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 72. SAUDI ARABIA DERMATOLOGICALS MARKET REVENUE, BY DERMATOLOGICAL DISEASE, 2018–2026 ($MILLION)
TABLE 73. SAUDI ARABIA DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026 ($MILLION)
TABLE 74. SAUDI ARABIA DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 75. REST OF LAMEA DERMATOLOGICALS MARKET REVENUE, BY DERMATOLOGICAL DISEASE, 2018–2026 ($MILLION)
TABLE 76. REST OF LAMEA DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026 ($MILLION)
TABLE 77. REST OF LAMEA DERMATOLOGICALS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 78. LAMEA DERMATOLOGICALS MARKET REVENUE, BY DERMATOLOGICAL DISEASE, 2018–2026($MILLION)
TABLE 79. LAMEA DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026($MILLION)
TABLE 80. LAMEA DERMATOLOGICALS MARKET REVENUE, BY TYPE, 2018–2026($MILLION)
TABLE 81. ABBVIE: COMPANY SNAPSHOT
TABLE 82. ABBVIE: OPERATING SEGMENTS
TABLE 83. ABBVIE: PRODUCT PORTFOLIO
TABLE 84. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 85. ASTRAZENECA: OPERATING BUSINESS SEGMENT
TABLE 86. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 87. AMGEN: COMPANY SNAPSHOT
TABLE 88. AMGEN: OPERATING SEGMENT
TABLE 89. AMGEN: PRODUCT PORTFOLIO
TABLE 90. GSK: COMPANY SNAPSHOT
TABLE 91. GSK: OPERATING BUSINESS SEGMENTS
TABLE 92. GSK: PRODUCT PORTFOLIO
TABLE 93. J&J: COMPANY SNAPSHOT
TABLE 94. J&J: OPERATING SEGMENTS
TABLE 95. JOHNSON & JOHNSON: PRODUCT PORTFOLIO:
TABLE 96. LEO: COMPANY SNAPSHOT
TABLE 97. LEO: OPERATING BUSINESS SEGMENTS
TABLE 98. LEO: PRODUCT PORTFOLIO
TABLE 99. MERCK: COMPANY SNAPSHOT
TABLE 100. MERCK: OPERATING BUSINESS SEGMENTS
TABLE 101. MERCK: PRODUCT PORTFOLIO
TABLE 102. NESTLÉ: COMPANY SNAPSHOT
TABLE 103. NESTLÉ: PRODUCT PORTFOLIO
TABLE 104. NOVARTIS: COMPANY SNAPSHOT
TABLE 105. NOVARTIS: OPERATING SEGMENTS
TABLE 106. NOVARTIS: PRODUCT PORTFOLIO
TABLE 107. PFIZER: COMPANY SNAPSHOT
TABLE 108. PFIZER: OPERATING SEGMENTS
TABLE 109. PFIZER: PRODUCT PORTFOLIO
Similar Reports
This new 68-country report from LeadingMarketResearch.com is available by region, country, market segment, section, or individual test.
The report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the global blood banking market during the next five years, and assist industry executives in developing effective business, new ...
- Publish Date: March 2, 2020
- $0
Hearing aids in the form of analog units have been traditionally present and used in India. Digital hearing units are finding increased growth in acceptability owing to the changing perceptions and growing base of the target consumer group. The Indian market is largely dependent on imports from foreign countries; domestic players in the country are ramping up their manufacturing facilities. The gr...
- Publish Date: March 10, 2011
- $950
The Indian medical devices market is largely dependent on imports from foreign countries. Although domestic players in the country are ramping up their manufacturing facilities, the foreign companies continue to enjoy a superior market share on account of their brand recognition, reliability, and technological superiority. The growing target base of consumers will boost sales and the market is exp...
- Publish Date: July 18, 2011
- $950
